Immunity Pharma Ltd. (IPL) is a privately-held clinical-stage neurology-focused biopharmaceutical company that develops therapies for neurodegenerative diseases, with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL's drugs are biologically active peptides that stimulate therapeutic cell-signaling processes which are down-regulated in neurodegenerative diseases. These drugs mitigate progression of neurodegenerative diseases by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis). IPL's drugs are being developed as treatment for ALS, Parkinson's disease and other neurodegenerative diseases.
| Website | https://immunitypharma.com |
| Revenue | $5 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2007 |
| Industry | Drug Stores & Pharmacies, Health Care, Retail |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Immunity Pharma Ltd employee's phone or email?
Immunity Pharma Ltd Questions
The Immunity Pharma Ltd annual revenue was $5 million in 2026.
Immunity Pharma Ltd is based in Jerusalem, Jerusalem.
The NAICS codes for Immunity Pharma Ltd are [3254, 325, 32541, 32].
The SIC codes for Immunity Pharma Ltd are [283, 28].
